In reference to Intranasal Corticosteroid Treatment on Recovery of Long‐Term Olfactory Dysfunction Due to COVID‐19

Abstract

This is a commentary on the article by Hosseinpoor et al. Laryngoscope , 2022

Therapies for COVID-19-Related Persistent Olfactory Disorders: One of the Good Fruits of the Pandemic

“…Kasiri et al [ 26 ] and Hintschich et al [ 27 ] treated patients with persistent ODs after SARS-CoV-2 infection with mometasone furoate as in our study without detecting significant benefits. This was confirmed by the recent meta-analysis of Kim et al [ 30 ] and is likely related to poor delivery of the corticosteroid spray to the olfactory epithelium [ 31 , 32 ]. Similarly, oral corticosteroids also did not demonstrate a clear advantage in terms of olfactory recovery compared to olfactory training alone [ 28 ].…”

Exploring the research landscape of COVID-19-induced olfactory dysfunction: A bibliometric study

“…In addressing OD in patients with neocoronary pneumonia, a range of therapeutic approaches have been evaluated, including oral supplementation, topical medications, nasal rinses, and olfactory training. Hosseinpoor et al (2022) and Vaira et al (2022) studied the effect of intranasal corticosteroid treatment on long-term OD recovery caused by COVID-19. At the same time, Veronese et al (2022) found that the combination of olfactory rehabilitation and oral supplementation of palmitoyl ethanolamine and lidocaine can improve the treatment effect of post-conjunctivitis OD.…”